Press release
North America Biosimilars Market Predicted to grow at a CAGR of 31.19% by 2025 | Key Players - Wockhardt Ltd, Sandoz International GmbH, Hospira, Inc., Teva Pharmaceutical Industries Ltd., Biocon Limited, Dr. Reddy’s Laboratories, Zydus Cadila, Mylan In
North America Biosimilars Market
Size of the North America Biosimilars Market size was valued at USD 2 million in 2018 and this figure estimated to cross USD 13 Million by the end of 2025, and it is growing at a CAGR of 31.19% during the forecast period 2019-2025. Biosimilars are formed by using living cells that treat disease, by recombinant DNA technology and controlled gene expression. Largest biosimilars are derived from bacteria, viruses, plants, and animals. Biosimilar drugs are used in the prevention and cure of various diseases such as rheumatoid arthritis, cancer, chronic kidney failure, oncology, diabetes, heart attacks, autoimmune diseases, growth hormone deficiency, and infectious disease.
Browse details of 140 number of pages research report developed on North America Biosimilars Market Research Report @ https://www.researchcosmos.com/reports/north-america-biosimilars-market/72699030
Drivers and Restraints:
Biosimilars are beginning as one of the most important sectors in the healthcare industry. With growing healthcare costs, biosimilars are being looked upon as an affordable treatment option. Growing prosperity is observing comprehensive growth in the biosimilars industry from demanding clinical needs of therapeutics. Rise in GDP and healthcare expenditures, and the demand for cost-effective therapeutics solution has resulted in the growth of this market in North America.
Major parts that are driving the market growth are next-gen business, high growth in chronic diseases, and less cost biosimilar drugs. Still, high initial investments in research hinder the growth of the protein expression market.
Biosimilars offer a poorer alternative for other biological and synthetic drugs. Extended co-operation between manufacturing companies and the outsourcing of biosimilar products are acting as a reason for the market demand. Still, high manufacturing cost and complexity, and the availability of low-priced generic drugs in the market are some of the major restraints the market is facing. Numerous companies are fraught with approvals for their biosimilar drugs, due to the unavailability of favorable regulatory compliance and heavy opposition from the reference product manufacturers. Moreover, consumer preferences and the prescription patterns of physicians in the United States are more inclined towards reference products.
Ask Free Sample of the Report @ https://www.researchcosmos.com/request/north-america-biosimilars-market/72699030
Geographical Insights:
Based on geography, the North American market is analyzed in the regions of Canada and the United States. North America is expected to lead this market during the forecast period due to increasing efforts by manufacturers to take advantage of growth opportunities in the United States and Canada. The FDA in the USA approved the first biosimilar product, Zarxio (filgrastim-side), in March 2015. The United States biosimilar regulatory route was created in March 2009 and since then the region has gained significant momentum, presenting new opportunities and challenges.
Key Players Profiled in this North America Biosimilars Market report are: Wockhardt Ltd, Sandoz International GmbH, Hospira, Inc., Teva Pharmaceutical Industries Ltd., Biocon Limited, Dr. Reddy’s Laboratories, Zydus Cadila, Mylan Inc., Celltrion Inc., Roche Diagnostics and Cipla Ltd.
For any queries, inquire more @ https://www.researchcosmos.com/inquire/north-america-biosimilars-market/72699030
Research Cosmos is a provider of standard and customized Industry research, business intelligence and consulting services across more than 100 domains in different industries of the world. We host the trending Industry reports of the world’s top-notch publishing companies, offering services to a wide range of customers from students to fortune 500 companies and discloses the hidden opportunities in every leading industry of the world.
Kevin Stewart
kevin@researchcosmos.com
Global Sales Manager
Research Cosmos
www.researchcosmos.com
+1 888 709 8757
U.S Office:
4390 U.S 1, Suite 211,
Princeton, NJ 08540.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release North America Biosimilars Market Predicted to grow at a CAGR of 31.19% by 2025 | Key Players - Wockhardt Ltd, Sandoz International GmbH, Hospira, Inc., Teva Pharmaceutical Industries Ltd., Biocon Limited, Dr. Reddy’s Laboratories, Zydus Cadila, Mylan In here
News-ID: 1724282 • Views: …
More Releases from Research Cosmos
Mobile Phone Insurance Market Size to Reach USD 32.24 Bn By 2025
The size of the Global mobile phone insurance market is estimated to reach USD 32.24 billion by 2025, growing at a CAGR of 12.5%, as per the recently published report by Research Cosmos. It is worth to claim insurance for mobile phones as we are spending a lot of money on purchasing. The policies include accidental damage, water damage, and screen cracking.
Browse details of the report @ https://www.researchcosmos.com/reports/mobile-phone-insurance-market/199557834
Growing utilization…
Social Employee Recognition Systems Market Predicted to grow at a CAGR of xx By …
Social Employee Recognition Systems Market Analysis Size, Growth rate and Overview:
Social Employee Recognition Systems Market was valued at USD xx million in 2018 and is expected to reach almost USD xx million by the end of 2025, growing at a CAGR of around xx% over the predicted period.
Throughout the world, social employee recognition systems have expanded dramatically to address the need to move away from traditional methods and programs of…
More Releases for Biosimilar
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Biosimilar Insulin Market Access
Boston, MA
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer…
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants…
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development
Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin
Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact…
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of…
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.…
